[Orlando, FL, October 12, 2019] — Israel-based Sight Diagnostics has chosen bioaccess™ as its regulatory and market access partner to obtain marketing authorization at Colombia's INVIMA towards the commercialization of its innovative point-of-care blood diagnostic device, OLO. The OLO device uses artificial intelligence (AI) to optically read small amounts of blood and provide complete blood count tests during a single doctor’s visit. In 2018, Sight Diagnostics received its CE mark and begun selling its OLO device in Europe and other countries. Sight is aiming for FDA approval and hopes to be marketing the test to hospitals and doctors’ offices in the US by 2020.

OlO uses machine vision to identify and count the different types of cells found in the blood. The device, which is roughly the size of a toaster oven, was designed to perform the analysis with the small amount of blood that comes from a single finger prick, but it can also analyze venous blood if a patient is having traditional blood draw for multiple tests. OlO finishes the analysis in about 10 minutes.

###

About Sight Diagnostics

Sight's mission is to change this reality by bringing affordable, accurate diagnostics to point-of-care. Our proprietary machine-vision based technology allows healthcare providers to perform multiple tests on a single, easy-to-operate platform. Read more at www.sightdx.com.

About bioaccess™

bioaccess™ is a Florida-based clinical research organization (CRO) and market access consulting company which mission is to help innovative life science companies conduct clinical research and commercialize their innovations in Colombia and the rest of Latin America. Read more at www.bioaccessla.com.